Infinity to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

22 Nov 2021
www.biospace.com
First in Class
Nov. 22, 2021 13:35 UTC CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer, today announced that Adelene Perkins, Chief Executive Officer, will present at the upcoming Piper Sandler 33rd Annual Virtual Healthcare Conference. The presentation will be a fireside chat with Ted Tenthoff, Piper’s Senior Biotech Analyst, which will be available on the Company’s website beginning November 22nd. Management will also be available for 1-on-1 meetings with investors during the conference which will take place November 29th through December 2nd. Presentation details can be found below: 33rd Annual Virtual Healthcare Conference Format: Presentation and 1-on-1 meetings Date and Time: Presentation available starting Monday, November 22nd at 10:00am ET; 1-on-1 meetings November 29th – December 2nd The presentations and archived webcasts can be accessed in the Investors/Media section of Infinity's website at and will be available on Infinity's website for 30 days following the event. About Infinity and Eganelisib Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a potentially first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which addresses a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (AB928, a dual adenosine receptor antagonistadenosine receptor antagonist) plus Doxil® in advanced TNBC patients. In 2019, Infinity completed enrollment in MARIO-1, a Phase 1/1b study evaluating eganelisib as a monotherapy and in combination with Opdivo (nivolumab) in patients with advanced solid tumors including patients refractory to checkpoint inhibitor therapy. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at . Opdivo® is a registered trademark of Bristol Myers Squibb. Tecentriq® is a registered trademark of Genentech, Inc. Abraxane® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company. Avastin® is a registered trademark of Genentech, Inc. Doxil® is a registered trademark of Baxter Healthcare Corporation.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.